ArticleGastroenterology & hepatology2017
Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.
Article in Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment.Cancer research · 2025Article
- A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.Journal of cancer immunology · 2024Article
- Role of Therapeutic Endoscopic Ultrasound in Management of Pancreatic Cancer: An Endoscopic Oncologist Perspective.Cancers · 2023Review
- The Performance Comparison ofMolecular imaging and biology · 2022Article
- Diagnostic Significance of Serum Fatty Acid Synthase in Patients with Pancreatic Cancer.Middle East journal of digestive diseases · 2021Article
- Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer.JCO clinical cancer informatics · 2021Article
- Serum N-Glycome analysis reveals pancreatic cancer disease signatures.Cancer medicine · 2020Article
- Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer.International journal of molecular sciences · 2020Review
- Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells.Cancer science · 2019Article
- Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome.Pancreas · 2019Article
- RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.Scientific reports · 2019Article
- High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
It is well known that pancreatic ductal adenocarcinoma has a high mortality rate. Despite progress in understanding the biology and genetic basis of this disease, life expectancy has changed minimally in the last 50 years. This article highlights the importance of screening patients at high risk for developing pancreatic cancer and reviews current methods as well as methods in development for pancreatic cancer early detection and surveillance.
Indexed as
Identifiers
28656024PMC5479340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.